Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX001899 vs docetaxel in previously treated KRAS G12C-mutated advanced NSCLC
CTR20244097Phase 3Active
- Sponsor
- Zhejiang Hangyu Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sosimerasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Zhejiang Hangyu Pharmaceutical. Primary endpoint: Progression-free survival (PFS) by independent assessment. Started Dec 2025; status: active.
02
Drugs
sosimerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244097.